Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study

Thumbnail
Metadata only
Author
Rottenburger, Christof
Nicolas, Guillaume P.
McDougall, Lisa
Kaul, Felix
Cachovan, Michal
Vija, A. Hans
Schibli, Roger
Geistlich, Susanne
Schumann, Anne
Rau, Tilman
Glatz, Katharina
Béhé, Martin
Christ, Emanuel R.
Wild, Damian
Show all
Date
2020-04
Type
    Journal Article
Publication status
published
External links
Journal / series
The Journal of Nuclear Medicine
Volume
61(4)
Pages / Article No.
520 - 526
Publisher
Society of Nuclear Medicine
Subject
cholecystokinin 2 receptor targeting; peptide receptorradionuclide therapy; 177Lu-PP-F11N; theranostics
Organisational unit
03688 - Schibli, Roger / Schibli, Roger  
03688 - Schibli, Roger / Schibli, Roger  
More
Show all metadata
Citations
Cited null times in Web of Science
Cited 8 times in Scopus
ETH Bibliography
yes
Altmetrics